Skip to main navigation
Skip to search
Skip to main content
UTMB Health Research Expert Profiles Home
Help & FAQ
Home
Experts
Departments
Equipment
Projects/Grants
Publications
Activities
Press/Media
Honors
Impacts
Search by expertise, name or affiliation
IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia
Anand Padmanabhan
, Curtis G. Jones
, Shannon M. Pechauer
, Brian R. Curtis
, Daniel W. Bougie
, Mehraboon S. Irani
, Barbara Bryant
, Jack B. Alperin
, Thomas G. Deloughery
, Kevin P. Mulvey
, Binod Dhakal
, Renren Wen
, Demin Wang
, Richard H. Aster
Pathology
Internal Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
103
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Additional Therapy
10%
Alternative Anticoagulants
10%
Antibody Binding
10%
Antibody-mediated
10%
Anticoagulant Therapy
10%
Antigen Binding
10%
Bleeding Risk
10%
Common Polymorphism
10%
Constant Domain
10%
Direct Oral Anticoagulants
10%
Disease Course
10%
Enzyme-linked Immunosorbent Assay (ELISA)
10%
Genotype
20%
Heparin-induced Thrombocytopenia
100%
High Dose
10%
IgG Fc
10%
IgG Receptors
10%
Immediate Response
10%
Immunoassay
10%
Induced Activation
10%
Intravenous Immunoglobulin (IVIg)
100%
Long-term Anticoagulation
10%
Mechanism of Action
10%
Patient Demographics
10%
Platelet Activation
20%
Platelet Factor 4
10%
Platelets
30%
Polymorphism
10%
Severe Disease
10%
Severe Thrombocytopenia
10%
Severely Affected
10%
Solid Phase
10%
Sustained Response
10%
Thrombocytopenia
10%
Thromboembolism
10%
Thrombosis
10%
Treatment Challenges
10%
Biochemistry, Genetics and Molecular Biology
Anticoagulation
12%
Antigen Binding
25%
Drug Megadose
12%
Enzyme
12%
Genotyping
12%
Heparin-Induced Thrombocytopenia
100%
Immunoassay
25%
Platelet
37%
Platelet Factor 4
12%
Thrombocyte Activation
25%
Thrombocytopenia
25%
Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulant Agent
12%
Anticoagulation Therapy
12%
Direct Oral Anticoagulant
12%
Disease Course
12%
Diseases
12%
Heparin Induced Thrombocytopenia
100%
Immunoassay
25%
Receptor
12%
Refractory Thrombocytopenia
12%
Thrombocyte Factor 4
12%
Thrombocytopenia
12%
Thromboembolism
12%
Thrombosis
12%
Immunology and Microbiology
Anticoagulation
12%
Antigen Binding
25%
Drug Megadose
12%
Heparin Induced Thrombocytopenia
100%
Immunoassay
25%
Platelet
37%
Platelet Factor 4
12%
Susceptibility
12%
Thrombocyte Activation
25%